Monday, January 14, 2019 2:45:04 PM
And there are also Blather Breathers that pretend they are independent thinkers, just give the middle a chance.
To make a statement that RGBP could fail or succeed is ludicrous. Implication: there is a 50-50 chance.
Any person that has traded for a minimum of time can look at
1- Balance Sheet (Fundamentals): RGBP is insolvent
2- Price Action (Technicals) RGBP is approaching -100% YOY.
3- Management (Momentum): RGBP's mgm't has been in the game for about a decade and failed at every step. More importantly, this management has failed investors at every step.
4- Patents (Contrarian): OK.... they have patents like so many before, HemaX, right. Of the current crop, Lilly offered them a librarian card (speaks for itself). Also if you have the homework done, you would see there are well over 150 ongoing FDA current trials in this particular field. These trials are being done by big pharma, other pharma with partnerships in place, and small bio-techs with financing in place.
It's almost delusional to think that RGBP can overcome even one the above elements...... oooops, IMO that is not their mission. It is a PR company designed to keep investors sending their $ so Konman Koos can keep that $300K yearly salary....not based on one product or sale; just his pr's
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM